Yipinhong Pharmaceutical Co Ltd Class A

300723.CS▼

Yipinhong Releases 2026 Interim Report: Net Profit of 485 Million Yuan

Yipinhong released its 2026 interim report on August 27, 2026. During the reporting period, the company achieved total operating revenue of 492 million yuan, a decrease of 92.0799 million yuan compared with the same period last year, down 15.77 percent year on year. Net profit attributable to the parent company was 485 million yuan. Net cash inflow from operating activities was 94.9489 million yuan. The company's latest asset-liability ratio was 58.11 percent, up 0.08 percentage points from the previous quarter. Gross margin was 57.44 percent, down 8.64 percentage points from the previous quarter and down 0.84 percentage points from the same period last year. Return on equity was 26.27 percent, and diluted earnings per share was 1.07 yuan. Total asset turnover was 0.12 times, and inventory turnover was 0.99 times. The number of shareholders was 33,100, and the top ten shareholders held 69.02 percent of total share capital.

300723.CS ▼

Jiemian·13hRead more ▾

Biotech & Genomic Medicine▲3

Yipinhong Subsidiary's Innovative Drug APH03867 Tablets Gets Clinical Trial Approval

The clinical trial application for the innovative drug APH03867 tablets, independently developed by Guangzhou Yipinhong Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Yipinhong, has been approved by the National Medical Products Administration, which has agreed to conduct clinical trials for the indication of gout with hyperuricemia.

300723.CS ▲

Biotech & Genomic Medicine

南方财经网·6dRead more ▾

Biotech & Genomic Medicine▲4

Yipinhong Subsidiary's Innovative Drug APH04935 Tablets Receive Clinical Trial Approval

Yipinhong announced that its wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical, has received approval from the National Medical Products Administration to conduct clinical trials for its independently developed innovative drug APH04935 tablets, intended for weight control and long-term weight management. The drug is a highly selective small-molecule GLP-1 receptor agonist, classified as a Class 1 innovative chemical drug, and has not been marketed domestically or internationally.

300723.CS ▲

Biotech & Genomic Medicine

CLS·9dRead more ▾

Biotech & Genomic Medicine▲

Yipinhong Subsidiary's Innovative Drug APH04935 Tablets Receive Clinical Trial Approval

Guangzhou Yipinhong Pharmaceutical Co., Ltd., a wholly owned subsidiary of Yipinhong, has received clinical trial approval from the National Medical Products Administration for its independently developed innovative drug APH04935 tablets. The drug is a highly active, highly selective small-molecule GLP-1R agonist, intended to become a once-daily oral small-molecule GLP-1R agonist for weight control and long-term weight management. The company has received the Drug Clinical Trial Approval Notice and will soon commence clinical trials.

300723.CS ▲

Biotech & Genomic Medicine

北京商报·9dRead more ▾

300723.CS▲

Two Yipinhong Drugs Tentatively Selected for the 12th National Centralized Drug Procurement

Yipinhong announced that its wholly-owned subsidiary Guangzhou Yipinhong Pharmaceutical's isavuconazonium sulfate for injection and Guangzhou Lianrui Pharmaceutical's perindopril amlodipine tablets (III) have been tentatively selected for the 12th National Centralized Drug Procurement. Isavuconazonium sulfate for injection had sales revenue of zero yuan in 2025, while perindopril amlodipine tablets (III) achieved sales revenue of 3.4817 million yuan, accounting for 0.37% of the company's 2025 operating revenue. In the first quarter of 2026, Yipinhong recorded revenue of 385 million yuan and net profit attributable to the parent of 594 million yuan.

300723.CS ▲

财中社·24dRead more ▾

300723.CS▲

Yipinhong Subsidiary Commissions Boji Medical to Conduct Clinical Study for Innovative Drug, Contract Value 6.5 Million Yuan

Yipinhong's wholly owned subsidiary, Yipinhong Pharmaceutical, plans to sign a technical service contract with Boji Medical, commissioning it to conduct a clinical study for the innovative drug APH04935 tablets. The total contract value is 6.5 million yuan, tax inclusive. This transaction constitutes a related-party transaction because Yipinhong's independent director Zhang Kejian also serves as a non-independent director of Boji Medical. In the first quarter of 2026, Yipinhong achieved revenue of 385 million yuan and net profit attributable to the parent company of 594 million yuan.

300723.CS ▲300404.CS ▲

财中社·34dRead more ▾

Biotech & Genomic Medicine▲3

Yipinhong Subsidiary Receives Drug Registration Certificate for Benzbromarone Tablets

Yipinhong announced that its wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical, has recently obtained the drug registration certificate for Benzbromarone Tablets issued by the National Medical Products Administration. The drug is a chemical drug in Category 3, with a specification of 50 mg, indicated for primary hyperuricemia and the intercritical period of gouty arthritis, and is listed as a Category B product under national medical insurance. According to data from Menet, the sales of benzbromarone in China's urban and county-level public hospitals in 2025 were approximately 269 million yuan. In the first quarter of 2026, Yipinhong achieved revenue of 385 million yuan and net profit attributable to the parent company of 594 million yuan.

300723.CS ▲

Biotech & Genomic Medicine

财中社·35dRead more ▾